RPE transplantation and its role in retinal disease

Lyndon da Cruz, Fred K. Chen, Ahmad Ahmado, John Greenwood, Pete Coffey

Research output: Contribution to journalReview article

176 Citations (Scopus)

Abstract

Retinal pigment epithelial (RPE) transplantation aims to restore the subretinal anatomy and re-establish the critical interaction between the RPE and the photoreceptor, which is fundamental to sight. The field has developed over the past 20 years with advances coming from a large body of animal work and more recently a considerable number of human trials. Enormous progress has been made with the potential for at least partial restoration of visual function in both animal and human clinical work. Diseases that have been treated with RPE transplantation demonstrating partial reversal of vision loss include primary RPE dystrophies such as the merTK dystrophy in the Royal College of Surgeons (RCS) rat and in humans, photoreceptor dystrophies as well as complex retinal diseases such as atrophic and neovascular age-related macular degeneration (AMD). Unfortunately, in the human trials the visual recovery has been limited at best and full visual recovery has not been demonstrated. Autologous full-thickness transplants have been used most commonly and effectively in human disease but the search for a cell source to replace autologous RPE such as embryonic stem cells, marrow-derived stem cells, umbilical cord-derived cells as well as immortalised cell lines continues. The combination of cell transplantation with other modalities of treatment such as gene transfer remains an exciting future prospect. RPE transplantation has already been shown to be capable of restoring the subretinal anatomy and improving photoreceptor function in a variety of retinal diseases. In the near future, refinements of current techniques are likely to allow RPE transplantation to enter the mainstream of retinal therapy at a time when the treatment of previously blinding retinal diseases is finally becoming a reality. (C) 2007 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)598-635
Number of pages38
JournalProgress in Retinal and Eye Research
Volume26
Issue number6
DOIs
Publication statusPublished - Nov 2007

Cite this

da Cruz, Lyndon ; Chen, Fred K. ; Ahmado, Ahmad ; Greenwood, John ; Coffey, Pete. / RPE transplantation and its role in retinal disease. In: Progress in Retinal and Eye Research. 2007 ; Vol. 26, No. 6. pp. 598-635.
@article{f2bbd5397ff845cf856061f1a606abc3,
title = "RPE transplantation and its role in retinal disease",
abstract = "Retinal pigment epithelial (RPE) transplantation aims to restore the subretinal anatomy and re-establish the critical interaction between the RPE and the photoreceptor, which is fundamental to sight. The field has developed over the past 20 years with advances coming from a large body of animal work and more recently a considerable number of human trials. Enormous progress has been made with the potential for at least partial restoration of visual function in both animal and human clinical work. Diseases that have been treated with RPE transplantation demonstrating partial reversal of vision loss include primary RPE dystrophies such as the merTK dystrophy in the Royal College of Surgeons (RCS) rat and in humans, photoreceptor dystrophies as well as complex retinal diseases such as atrophic and neovascular age-related macular degeneration (AMD). Unfortunately, in the human trials the visual recovery has been limited at best and full visual recovery has not been demonstrated. Autologous full-thickness transplants have been used most commonly and effectively in human disease but the search for a cell source to replace autologous RPE such as embryonic stem cells, marrow-derived stem cells, umbilical cord-derived cells as well as immortalised cell lines continues. The combination of cell transplantation with other modalities of treatment such as gene transfer remains an exciting future prospect. RPE transplantation has already been shown to be capable of restoring the subretinal anatomy and improving photoreceptor function in a variety of retinal diseases. In the near future, refinements of current techniques are likely to allow RPE transplantation to enter the mainstream of retinal therapy at a time when the treatment of previously blinding retinal diseases is finally becoming a reality. (C) 2007 Elsevier Ltd. All rights reserved.",
keywords = "retinal pigment epithelium, transplantation, review, age-related macular degeneration, surgery, retinal dystrophy, PIGMENT EPITHELIAL-CELLS, EMBRYONIC STEM-CELLS, SUBFOVEAL CHOROIDAL NEOVASCULARIZATION, SCANNING LASER OPHTHALMOSCOPE, OPTICAL COHERENCE TOMOGRAPHY, MACULAR TRANSLOCATION SURGERY, CONTRAST SENSITIVITY TEST, RETROVIRAL GENE-TRANSFER, HUMAN BRUCHS MEMBRANE, 360-DEGREES PERIPHERAL RETINECTOMY",
author = "{da Cruz}, Lyndon and Chen, {Fred K.} and Ahmad Ahmado and John Greenwood and Pete Coffey",
year = "2007",
month = "11",
doi = "10.1016/j.preteyeres.2007.07.001",
language = "English",
volume = "26",
pages = "598--635",
journal = "Progress in Retinal and Eye Research",
issn = "1350-9462",
publisher = "Pergamon",
number = "6",

}

RPE transplantation and its role in retinal disease. / da Cruz, Lyndon; Chen, Fred K.; Ahmado, Ahmad; Greenwood, John; Coffey, Pete.

In: Progress in Retinal and Eye Research, Vol. 26, No. 6, 11.2007, p. 598-635.

Research output: Contribution to journalReview article

TY - JOUR

T1 - RPE transplantation and its role in retinal disease

AU - da Cruz, Lyndon

AU - Chen, Fred K.

AU - Ahmado, Ahmad

AU - Greenwood, John

AU - Coffey, Pete

PY - 2007/11

Y1 - 2007/11

N2 - Retinal pigment epithelial (RPE) transplantation aims to restore the subretinal anatomy and re-establish the critical interaction between the RPE and the photoreceptor, which is fundamental to sight. The field has developed over the past 20 years with advances coming from a large body of animal work and more recently a considerable number of human trials. Enormous progress has been made with the potential for at least partial restoration of visual function in both animal and human clinical work. Diseases that have been treated with RPE transplantation demonstrating partial reversal of vision loss include primary RPE dystrophies such as the merTK dystrophy in the Royal College of Surgeons (RCS) rat and in humans, photoreceptor dystrophies as well as complex retinal diseases such as atrophic and neovascular age-related macular degeneration (AMD). Unfortunately, in the human trials the visual recovery has been limited at best and full visual recovery has not been demonstrated. Autologous full-thickness transplants have been used most commonly and effectively in human disease but the search for a cell source to replace autologous RPE such as embryonic stem cells, marrow-derived stem cells, umbilical cord-derived cells as well as immortalised cell lines continues. The combination of cell transplantation with other modalities of treatment such as gene transfer remains an exciting future prospect. RPE transplantation has already been shown to be capable of restoring the subretinal anatomy and improving photoreceptor function in a variety of retinal diseases. In the near future, refinements of current techniques are likely to allow RPE transplantation to enter the mainstream of retinal therapy at a time when the treatment of previously blinding retinal diseases is finally becoming a reality. (C) 2007 Elsevier Ltd. All rights reserved.

AB - Retinal pigment epithelial (RPE) transplantation aims to restore the subretinal anatomy and re-establish the critical interaction between the RPE and the photoreceptor, which is fundamental to sight. The field has developed over the past 20 years with advances coming from a large body of animal work and more recently a considerable number of human trials. Enormous progress has been made with the potential for at least partial restoration of visual function in both animal and human clinical work. Diseases that have been treated with RPE transplantation demonstrating partial reversal of vision loss include primary RPE dystrophies such as the merTK dystrophy in the Royal College of Surgeons (RCS) rat and in humans, photoreceptor dystrophies as well as complex retinal diseases such as atrophic and neovascular age-related macular degeneration (AMD). Unfortunately, in the human trials the visual recovery has been limited at best and full visual recovery has not been demonstrated. Autologous full-thickness transplants have been used most commonly and effectively in human disease but the search for a cell source to replace autologous RPE such as embryonic stem cells, marrow-derived stem cells, umbilical cord-derived cells as well as immortalised cell lines continues. The combination of cell transplantation with other modalities of treatment such as gene transfer remains an exciting future prospect. RPE transplantation has already been shown to be capable of restoring the subretinal anatomy and improving photoreceptor function in a variety of retinal diseases. In the near future, refinements of current techniques are likely to allow RPE transplantation to enter the mainstream of retinal therapy at a time when the treatment of previously blinding retinal diseases is finally becoming a reality. (C) 2007 Elsevier Ltd. All rights reserved.

KW - retinal pigment epithelium

KW - transplantation

KW - review

KW - age-related macular degeneration

KW - surgery

KW - retinal dystrophy

KW - PIGMENT EPITHELIAL-CELLS

KW - EMBRYONIC STEM-CELLS

KW - SUBFOVEAL CHOROIDAL NEOVASCULARIZATION

KW - SCANNING LASER OPHTHALMOSCOPE

KW - OPTICAL COHERENCE TOMOGRAPHY

KW - MACULAR TRANSLOCATION SURGERY

KW - CONTRAST SENSITIVITY TEST

KW - RETROVIRAL GENE-TRANSFER

KW - HUMAN BRUCHS MEMBRANE

KW - 360-DEGREES PERIPHERAL RETINECTOMY

U2 - 10.1016/j.preteyeres.2007.07.001

DO - 10.1016/j.preteyeres.2007.07.001

M3 - Review article

VL - 26

SP - 598

EP - 635

JO - Progress in Retinal and Eye Research

JF - Progress in Retinal and Eye Research

SN - 1350-9462

IS - 6

ER -